COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (ASPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03662035
Recruitment Status : Unknown
Verified September 2018 by Kequn Xu, Changzhou No.2 People's Hospital.
Recruitment status was:  Not yet recruiting
First Posted : September 7, 2018
Last Update Posted : September 19, 2018
Information provided by (Responsible Party):
Kequn Xu, Changzhou No.2 People's Hospital

Brief Summary:
The aim of this study was to determine the efficacy and safety of apatinib combined with S-1 on advanced pancreatic cancer patients after failure of first-line chemotherapy.

Condition or disease Intervention/treatment Phase
Advanced Pancreatic Cancer Drug: Apatinib Drug: S-1 Phase 2

Detailed Description:
  1. To observe the curative efficacy of apatinib and S-1 on patients by analyzing the data of overall survival (OS), complete remission (CR) or partial remission (PR), the rate of progression free survival (PFS), levels of CA19-9 and VEGFR in serum [Time Frame: Evaluation at 2 month intervals through study completion from the date of study entry until the date of progression, up to 1 year].
  2. To observe any adverse events, including abnormal clinical symptoms and vital signs, abnormal laboratory examinations, and to record the clinical features, severity, occurrence time, duration, management and prognosis of all subjects during the clinical study, and to determine the correlation between these adverse events and the experimental drugs. . The safety of drugs used in advanced pancreatic cancer was evaluated by CTCAE v4.0

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
Estimated Study Start Date : September 15, 2018
Estimated Primary Completion Date : March 1, 2020
Estimated Study Completion Date : August 1, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: single-arm
Apatinib and S-1 Patients will be offered with Apatinib (500mg/d) and S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2) until their disease have progressed.
Drug: Apatinib


Patients with advanced pancreatic cancer after failure of first-line chemotherapy will receive Apatinib (500mg/d, orally) 30 minutes after meal with warm water.Take 21 days as a cycle, patients will receive this treatment until they have got disease progressed. Dose adjustment: with 3/4 level of adverse reactions, the dose should be lowered to 250 mg/d.

Drug: S-1


Patients will receive S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2, orally) twice a day, once after breakfast and once after dinner, for 14 days, 7 days for suspension and 21 days as one cycle.

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: one year. ]
    Progression-free survival is defined as the time from registration to the earlier of death or disease progression.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: one year. ]
    OS refers to the date of registration to the date of death for any cause.

  2. Duration of response [ Time Frame: one year. ]
    DOR refers to the time from the time the measurement first conforms to the CR or PR criteria (whichever is first measured) to the time the first true record of disease recurrence or progression (using the minimum measurements recorded in the trial as a reference for disease progression).

  3. Objective response rate [ Time Frame: one year. ]
    ORR refers to the proportion of patients whose tumors have shrunk to a certain extent for a certain period of time, including CR and PR cases

  4. Disease Control Rate [ Time Frame: one year. ]
    DCR refers to the percentage of patients with confirmed complete remission, partial remission, and disease stabilization (> 8 weeks) who can evaluate efficacy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • 18-70 years old;
  • ECOG score: 0-2;
  • Have confirmed metastatic or locally advanced unresectable pancreatic cancer;
  • At least one measurable lesion according to the RECIST1.1 standard;
  • First-line chemotherapy drugs do not include S-1 or fluorouracil drugs;
  • Main organ functions meet the following standards:

    • Baseline blood routine (the inspection standard should meet the requirements of no blood transfusion and blood products within 14 days, no use of G-CSF and other hematopoietic stimulant correction) :

      • Hemoglobin>80g/L
      • The absolute neutrophil count (ANC) 1.5 x 109 / L;
      • Blood platelet (PLT)> 90 x 109 / L;
    • Baseline biochemical test shall meet the following standards:

      • T BIL < 1.5*ULN.
      • A LT and AST<2.5*ULN, and in patients with liver metastasis < 5*ULN;
      • Cr≤1.5*ULN.
      • Albumin is greater than or equal to 30g/L;
  • Women of child-bearing age must already have access to reliable contraception. Pregnancy tests (serum or urine) were performed within 7 days prior to enrollment and the results were negative, and a reliable method of contraception was preferred 8 weeks after the trial period and the last drug administration;
  • Subjects will voluntarily join the study and sign the informed consent.

Exclusion criteria:

  • Clearly allergic to apatinib, S-1 or their excipients;
  • There are various factors affecting oral drugs (including dysphagia, chronic diarrhea, intestinal obstruction, etc.);
  • Serious heart diseases in the last six months, including :

    • angina;
    • myocardial infarction;
    • heart failure;
    • interphase of QTc >450ms;
    • any other heart diseases that were judged as unsuitable for the study;
  • Combined with uncontrollable hypertension after drug treatment (systolic blood pressure >140mmHg, diastolic blood pressure >90mmHg);
  • Complicated with other serious medical diseases, including cerebrovascular disease, uncontrolled infection, active peptic ulcer, intestinal obstruction, etc.;
  • Metastasis of tumor central nervous system;
  • Women during pregnancy and lactation;
  • The patient has been diagnosed with other tumors in the past five years, except for the following situations: B. Cured basal cell carcinoma of the skin and cured orthotopic carcinoma of the cervix;
  • The time from the last chemotherapy is shorter than 4 weeks or 5 half-life (the time taken is older), and the time from the last radiotherapy is shorter than 4 weeks;
  • Use the experimental drug within 28 days before enrollment;
  • Patients with grade 2 or above toxicity caused by the use of anti-tumor drugs before enrollment;
  • Have mental disorders or a history of substance abuse;
  • Other circumstances that the investigator deems inappropriate to participate in the study;
Layout table for additonal information
Responsible Party: Kequn Xu, Director, head of oncology department, principal investigator, clinical professor, Changzhou No.2 People's Hospital Identifier: NCT03662035    
Other Study ID Numbers: ChangzhouNo2
First Posted: September 7, 2018    Key Record Dates
Last Update Posted: September 19, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action